GRACE :: Global Resource for Advancing Cancer Education

Sally Church

Share

Sally Church MBA, Ph.D
Icarus Consultants, Inc.

Twitter: maverickNY
http://www.pharmastrategyblog.com


Sally is at heart a science geek.  Her early background in academic research and life science was instrumental to her subsequent success in the Pharma industry, where she spent over 13 years at Sandoz and Novartis in the UK and US, operating in a variety of different roles in the organisation.

 Her particular interests are in oncology, hematology and respiratory medicine, with a particular focus on targeted therapies based on rational drug design based upon a deeper understanding of the science and biology behind the disease:

As we learn more and more about the biology of cancer, so our ability to develop new drugs that target the abnormality with in the cancer cell alone leaving normal cells relatively unscathed is improving.  Biomarkers and improved diagnostics are also helping to facilitate this, which is essential with the increasing pressures on the healthcare systems and finite resources.  It’s no longer acceptable to launch a new drug and hope as many patients will be treated as possible. Now it is expected that companies will develop biomarkers and companion diagnostics to determine which patients are most likely to respond to a drug.  This raises the bar for new entrants while putting the focus back on innovation and science, for the better.  Smart scientists and marketers are working in collaboration to both speed up drug development and improve life cycle management, innovating and extending the life of a brand while improving patient outcomes.

At Novartis Oncology in the US, Sally was responsible for new product development for over a dozen agents in early development, one of which she worked on from phase I to phase IV, including marketing of several approvals in liquid and solid tumours.  The initial launch was announced by the Secretary of Health and Human Sciences on TV and appeared on the front cover of Time Magazine, becoming a poster child for novel and targeted cancer therapy.

Over the last seven years, Sally has run a marketing consultancy company specialising in oncology new product development working with a number of Pharma and Biotech clients in the US and EU. 


Conflicts of Interest

none


Ask Us, Q&A
Share

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Recent GRACE Forum Topics

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243